BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 37255065)

  • 1. Intravenous zoledronate for postmenopausal women with osteopenia and osteoporosis: a systematic review and metanalysis.
    Gazoni FM; Civile VT; Atallah ÁN; Santos FC; Trevisani VFM
    Sao Paulo Med J; 2023; 141(6):e2022480. PubMed ID: 37255065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
    Wells GA; Hsieh SC; Zheng C; Peterson J; Tugwell P; Liu W
    Cochrane Database Syst Rev; 2022 May; 5(5):CD004523. PubMed ID: 35502787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D.
    Hara T; Hijikata Y; Matsubara Y; Watanabe N
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013424. PubMed ID: 34231877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
    O'Donnell S; Cranney A; Wells GA; Adachi JD; Reginster JY
    Cochrane Database Syst Rev; 2006 Jul; (3):CD005326. PubMed ID: 16856092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial.
    Reid IR; Horne AM; Mihov B; Stewart A; Garratt E; Wiessing KR; Bolland MJ; Bastin S; Gamble GD
    J Intern Med; 2019 Aug; 286(2):221-229. PubMed ID: 30887607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
    Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
    Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of fracture prevention after zoledronate treatment in women with osteopenia: observational follow-up of a 6-year randomised controlled trial to 10 years.
    Reid IR; Horne AM; Mihov B; Bava U; Stewart A; Gamble GD
    Lancet Diabetes Endocrinol; 2024 Apr; 12(4):247-256. PubMed ID: 38452783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.
    Händel MN; Cardoso I; von Bülow C; Rohde JF; Ussing A; Nielsen SM; Christensen R; Body JJ; Brandi ML; Diez-Perez A; Hadji P; Javaid MK; Lems WF; Nogues X; Roux C; Minisola S; Kurth A; Thomas T; Prieto-Alhambra D; Ferrari SL; Langdahl B; Abrahamsen B
    BMJ; 2023 May; 381():e068033. PubMed ID: 37130601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
    Fink HA; MacDonald R; Forte ML; Rosebush CE; Ensrud KE; Schousboe JT; Nelson VA; Ullman K; Butler M; Olson CM; Taylor BC; Brasure M; Wilt TJ
    Ann Intern Med; 2019 Jul; 171(1):37-50. PubMed ID: 31009947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fracture Prevention with Zoledronate in Older Women with Osteopenia.
    Reid IR; Horne AM; Mihov B; Stewart A; Garratt E; Wong S; Wiessing KR; Bolland MJ; Bastin S; Gamble GD
    N Engl J Med; 2018 Dec; 379(25):2407-2416. PubMed ID: 30575489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of teriparatide and bisphosphonates on new fractures in postmenopausal women with osteoporosis: A protocol for systematic review and meta-analysis.
    Ouyang Y; Chen S; Wan T; Zheng G; Sun G
    Medicine (Baltimore); 2021 Feb; 100(7):e24839. PubMed ID: 33607854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates in multiple myeloma: a network meta-analysis.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
    Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
    Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
    O'Donnell S; Cranney A; Wells GA; Adachi JD; Reginster JY
    Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD005326. PubMed ID: 17054253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin K to prevent fractures in older women: systematic review and economic evaluation.
    Stevenson M; Lloyd-Jones M; Papaioannou D
    Health Technol Assess; 2009 Sep; 13(45):iii-xi, 1-134. PubMed ID: 19818211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial.
    Grey A; Bolland MJ; Horne A; Mihov B; Gamble G; Reid IR
    CMAJ; 2017 Sep; 189(36):E1130-E1136. PubMed ID: 28893875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains.
    Everts-Graber J; Reichenbach S; Ziswiler HR; Studer U; Lehmann T
    J Bone Miner Res; 2020 Jul; 35(7):1207-1215. PubMed ID: 31991007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
    Tan W; Sun J; Zhou L; Li Y; Wu X
    J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.